Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Werewolf Therapeutics Inc (NQ: HOWL )

3.550 +0.070 (+2.01%)
Streaming Delayed Price Updated: 9:55 AM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,363
Open 3.450
Bid (Size) 3.320 (1)
Ask (Size) 3.580 (3)
Prev. Close 3.480
Today's Range 3.400 - 3.550
52wk Range 1.390 - 7.510
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Werewolf Therapeutics to Present at the Jefferies Healthcare Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+73.17%
+73.17%
1 Month
+19.13%
+19.13%
3 Month
+39.22%
+39.22%
6 Month
+116.46%
+116.46%
1 Year
-29.14%
-29.14%

More News

Read More
Expert Ratings for Werewolf Therapeutics
Via Benzinga
Recap: Werewolf Therapeutics Q1 Earnings
Via Benzinga
Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Analyst Ratings for Werewolf Therapeutics
Via Benzinga
Werewolf Therapeutics to Participate in May Investor Conferences
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE™ Molecule, in Cancer Immunology Research
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
UPDATE -- Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2023
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Present at the SVB Securities Global Biopharma Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Over $4 Million Bet On Werewolf Therapeutics? Check Out These 4 Penny Stocks Insiders Are Buying
Via Benzinga
Why KNOT Offshore Partners Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Werewolf Therapeutics Presents Preclinical Data on mWTX-330, a Surrogate IL-12 INDUKINE™ Molecule, at the Society for Immunotherapy of Cancer Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Why Broadwind Shares Are Trading Higher By 85%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022
Via Benzinga
Werewolf Therapeutics to Present Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting and Participate in Upcoming Investor Conferences
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.